Form 4: Vistagen Director Edick Granted Stock Options

Vistagen Therapeutics Director Paul R. Edick received 35,200 stock options with an exercise price of $3.90, vesting over three years.

Summary

• Paul R. Edick, a Director of Vistagen Therapeutics, Inc. (VTGN), was granted 35,200 stock options.
• The stock options have an exercise price of $3.90 per share.
• The grant date for these options was October 27, 2025.
• The options were granted in connection with Mr. Edick's appointment to the Issuer's Board of Directors.
• The options were issued under Vistagen's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
• The options vest in three equal annual installments, with the first installment vesting on the first anniversary of the grant date.
• The expiration date for these stock options is October 27, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. It does not contain information that would significantly alter the company's financial outlook or operational status.

Positives

• The grant of stock options to Director Paul R. Edick aligns his interests with long-term shareholder value.
• The use of an established equity incentive plan (Amended and Restated 2019 Omnibus Equity Incentive Plan) demonstrates structured corporate governance for executive compensation.

Future Outlook

The stock options vest in three equal annual installments, beginning on the first anniversary of the grant date, indicating a long-term incentive structure for the director.

Management Comments

• The stock options were granted in connection with the reporting person's appointment to the Issuer's Board of Directors.

Industry Context

Granting stock options to directors as part of their compensation package is a common practice across industries, particularly in biotechnology and pharmaceutical sectors, to align leadership incentives with company performance and shareholder interests.

Comparison to Industry Standards

• The grant of stock options to a director upon appointment is a standard compensation practice, comparable to similar arrangements seen at other publicly traded biotechnology companies.
• The vesting schedule of three equal annual installments is a common structure designed to encourage long-term commitment and performance from board members.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The stock options will begin vesting on October 27, 2026, with subsequent installments on the following two anniversaries.

Key Dates

Keywords

Vistagen Therapeutics, VTGN, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Paul R. Edick